Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...